| Autor: |
Campagna R; Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy., Nonne C; Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy., Antonelli G; Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy., Turriziani O; Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. |
| Jazyk: |
angličtina |
| Zdroj: |
Viruses [Viruses] 2024 Oct 30; Vol. 16 (11). Date of Electronic Publication: 2024 Oct 30. |
| DOI: |
10.3390/v16111697 |
| Abstrakt: |
Despite its effectiveness in controlling plasma viremia, antiretroviral therapy (ART) cannot target proviral DNA, which remains an obstacle to HIV-1 eradication. When treatment is interrupted, the reservoirs can act as a source of viral rebound, highlighting the value of proviral DNA as an additional source of information on an individual's overall resistance burden. In cases where the viral load is too low for successful HIV-1 RNA genotyping, HIV-1 DNA can help identify resistance mutations in treated individuals. The absence of treatment history, the need to adjust ART despite undetectable viremia, or the presence of LLV further support the use of genotypic resistance tests (GRTs) on HIV-1 DNA. Conventionally, GRTs have been achieved through Sanger sequencing, but the advances in NGS are leading to an increase in its use, allowing the detection of minority variants present in less than 20% of the viral population. The clinical significance of these mutations remains under debate, with interpretations varying based on context. Additionally, proviral DNA is subject to APOBEC3-induced hypermutation, which can lead to defective, nonviable viral genomes, a factor that must be considered when performing GRTs on HIV-1 DNA. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
